Quick Answer
Spyre Therapeutics, Inc. reported Cash and Equivalents of $85.72 million for fiscal year 2025.
Spyre Therapeutics, Inc. Cash and Equivalents — Annual History
| Fiscal Year | Cash and Equivalents | YoY Change |
|---|---|---|
| 2025 | $85.72M | -4.1% |
| 2024 | $89.42M | -52.7% |
| 2023 | $188.89M | +441.8% |
| 2022 | $34.86M | +130.2% |
| 2021 | $15.14M | -83.2% |
| 2020 | $90.09M | +368.0% |
| 2019 | $19.25M | -14.3% |
| 2018 | $22.46M | +75.2% |
| 2017 | $12.82M | -73.2% |
| 2016 | $47.75M | +63.0% |
| 2015 | $29.29M | +1019.8% |
| 2014 | $2.62M | -43.1% |
| 2013 | $4.60M | — |
Quarterly Cash and Equivalents
| Quarter Ending | Cash and Equivalents | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $64.90M | -9.3% | -20.5% |
| June 30, 2025 | $81.66M | +80.9% | +68.4% |
| March 31, 2025 | $48.49M | -78.7% | -45.8% |
| December 31, 2024 | $89.42M | -52.7% | +24.9% |
| September 30, 2024 | $71.58M | -21.0% | +58.6% |
| June 30, 2024 | $45.14M | -80.8% | -80.2% |
| March 31, 2024 | $227.55M | +545.7% | +20.5% |
| December 31, 2023 | $188.89M | +441.8% | +108.5% |
- Spyre Therapeutics, Inc. showed a decrease of -4.1% in Cash and Equivalents compared to the prior fiscal year.
- Over the 2013–2025 period, Spyre Therapeutics, Inc.’s cash and equivalents has grown by 1764.7% (from $4.60 million to $85.72 million).
- The most recent figure is from Spyre Therapeutics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on February 19, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: